$INVO News
Last published 2y ago
- 2y agoINVONAYANAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular CarcinomaGlobeNewswireSARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune
- 2y agoINVOINVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA BiosciencesGlobeNewswireSARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (NASDAQ:INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune
- 2y agoINVOINVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)GlobeNewswireSARASOTA, Fla. and MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience ("INVO") (NASDAQ:INVO) today announced it has closed its merger with NAYA Biosciences, a company dedicated to increasing patient access to
- 2y agoINVOINVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDAGlobeNewswireSARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment
- 2y agoINVOINVO Reports Record First Quarter 2024 Financial ResultsGlobeNewswireSARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment
- 2y agoINVOINVO Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireSARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced
- 2y agoINVONAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood JournalPR NewswireNAYA Biosciences Inc. ("NAYA"), a company which has recently signed a definitive merger agreement with INVO Bioscience to establish an expanded,...
- 2y agoINVOINVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementPR NewswireINVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility...
- 2y agoINVOINVO Reports Record Third Quarter 2023 Financial ResultsPR NewswireINVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced...
- 3y agoINVONAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending MergerPR NewswireINVO Bioscience, Inc. (Nasdaq: INVO) ("INVO"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide,...
- 3y agoINVOINVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase WarrantsPR NewswireINVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility...
- 3y agoESMTHESINVOTGHMoore Kuehn Encourages INVO, ESMT, HES, and TGH Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoTCBPCVMINVOSNY+1Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary DevelopmentsPR NewswireAcute myeloid leukemia (AML) is a type of hematologic cancer that is distinguished by the clonal growth of myeloid blasts in the peripheral blood,...
- 3y agoINVOINVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science CompanyPR NewswireINVO Bioscience, Inc. (Nasdaq: INVO) ("INVO"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide,...
- 3y agoINVOINVO to Participate in the Lytham Partners Fall 2023 Investor ConferencePR NewswireSARASOTA, Fla., Oct. 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment
- 3y agoINVOINVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERSPR NewswireSARASOTA, Fla., Sept. 29, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company") today announced that its special meeting of shareholders on September 29, 2023 (the
- 3y agoINVOINVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ETPR NewswireSARASOTA, Fla., Sept. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment
- 3y agoINVOINVO Bioscience, Inc. (INVO) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoINVOINVO Reports Second Quarter 2023 Financial ResultsPR NewswireCompany to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Aug. 14, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company
- 3y agoINVOINVO Closes Acquisition of Wisconsin Fertility InstitutePR NewswireTransformational and accretive acquisition adds significant scale to INVO's current operations Contributes over $5 million in incremental annual revenue as well as positive net income and cash flows First significant
- 3y agoINVOINVO Bioscience Announces Closing of $4.5 Million Public OfferingPR NewswireSARASOTA, Fla., Aug. 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment
- 3y agoINVOINVO Bioscience Announces Pricing of $4.5 Million Public OfferingPR NewswireSARASOTA, Fla., Aug. 4, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment
- 3y agoINVOINVO Sets Revised Closing Date of Wisconsin Fertility Institute Acquisition and Announces Key Operational Trends to Drive Shareholder ValuePR NewswireCompany sets closing date deadline of acquisition to August 10, 2023 -- Acquisition is expected to significantly enhance total annual revenue and contribute positive net income to the company's operating
- 3y agoINVOINVO Announces a 1:20 Reverse Stock Split Effective Pre-Market Opening on July 28, 2023PR NewswireSARASOTA, Fla., July 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment
- 3y agoINVOINVO Receives 510(k) FDA Clearance for Expanded Use of the INVOcell DevicePR NewswireINVOcell now cleared for 5-day incubation period Supporting data reflects improved patient outcomes, similar to IVF SARASOTA, Fla., June 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the
- 3y agoINVOINVO Reports First Quarter 2023 Financial ResultsPR NewswireCompany to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 15, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused
- 3y agoINVOINVO Bioscience to Report First Quarter 2023 Financial Results on Monday, May 15, 2023PR NewswireFinancial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company
- 3y agoINVOINVO Reports Fourth Quarter and Full Year 2022 Financial ResultsPR NewswireCompany to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., April 17, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company
- 3y agoINVOINVO Bioscience to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Monday, April 17, 2023PR NewswireFinancial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., April 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company
- 3y agoINVOINVO Congratulates Wisconsin Fertility Institute on Being Named One of America's Best Fertility Clinics by NewsweekPR NewswireINVO recently announced the signing of binding agreements to acquire this top-rated clinic SARASOTA, Fla. and MADISON, Wis., April 5, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the
- 3y agoINVOINVO Provides Preliminary Update on FY2022 Financial ResultsPR NewswireSARASOTA, Fla., March 30, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment
- 3y agoINVOINVO Bioscience Announces Closing of $3.0 Million Registered Direct OfferingPR NewswireSARASOTA, Fla., March 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment
- 3y agoINVOINVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-MarketPR NewswireSARASOTA, Fla., March 24, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment
- 3y agoINVOINVO Signs Binding Agreements to Acquire Wisconsin Fertility InstitutePR NewswireAccretive acquisition expected to add significant scale to INVO's operations Contributes over $5 million in incremental annual revenue as well as positive net income Initial transaction that establishes acquisitions
- 3y agoINVOINVO Bioscience Enters Distribution Agreement for TaiwanPR NewswireSARASOTA, Fla., Jan. 5, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide
- 3y agoINVOINVO Bioscience Engages Nationally Recognized Physician for New Tampa-based INVO CenterPR NewswireShelly W. Holmström, M.D. FACOG, to serve as physician operator at soon to be opened Tampa-based INVO Center.The current metro area population of Tampa in 2022 is 2,945,000.INVO Centers focus on serving patients in need
- 3y agoINVOFirst Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive TechnologyPR NewswirePatient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF (cIVF) in Malaysia INVOcell provides an advanced, effective and affordable infertility treatment option to help increase
- 3y agoINVOINVO Bioscience Reports Third Quarter 2022 Financial ResultsPR NewswireCompany to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Nov. 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused
- 4y agoINVOINVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022PR NewswireFinancial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Nov. 10, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company
- 4y agoINVOINVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & ExpoPR Newswire- The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access
- 4y agoINVOINVOcell Review Published in Current Opinion in Obstetrics and GynecologyPR NewswireSARASOTA, Fla., Oct. 21, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device
- 4y agoINVOINVO Bioscience to Exhibit at the 2022 American Society for Reproductive Medicine (ASRM) Congress & ExpoPR NewswireSARASOTA, Fla. and ANAHEIM, Calif., Oct. 17, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC),
- 4y agoINVODr. Sue Ellen Carpenter of INVO Bioscience's Atlanta-based INVO Center - Bloom Fertility - Named Top Doctor by Castle ConnollyPR NewswireSARASOTA, Fla. and ATLANTA, Sept. 22, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal cult
- 4y agoINVOINVOcell Launched in Malaysia by Advanced Reproductive Centre, Hospital Canselor Tuanku MuhrizPR NewswireSARASOTA, Fla., Aug. 25, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") p
- 4y agoINVOINVO Bioscience Reports Second Quarter 2022 Financial ResultsPR NewswireCompany to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Aug. 15, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment world
- 4y agoINVOINVO Bioscience to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022PR NewswireFinancial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Aug. 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to adv
- 4y agoINVOINVO Bioscience Announces "Get to Know INVOcell" - a Series of Facebook Live Events Supporting Access to Affordable Fertility TreatmentPR NewswireMark Your Calendars for July 7, 2022, with Dr. Sue Ellen Carpenter of Atlanta-based Bloom Fertility SARASOTA, Fla., July 7, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focuse
- 4y agoINVOINVO Signs Distribution Agreement with Onesky Holding Limited for Mainland ChinaPR NewswireAgreement includes minimum purchase obligations upon product registration and approval SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding
- 4y agoINVOINVO Bioscience Reports First Quarter 2022 Financial ResultsPR NewswireCompany to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment world
- 4y agoINVOINVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022PR NewswireFinancial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 9, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to adva